DaVita Projects Q4 Operating Income Growth Despite Dialysis Volume Headwinds
DaVita expects fourth-quarter operating income to rise by about 30 million US dollars, driven by non-dialysis growth that offsets softer treatment volumes.
DaVita Inc. management addressed investors at the Wolfe Research Healthcare Conference on Tuesday, November 10, 2026, outlining a mixed operational backdrop. Chief Financial Officer Joel Ackerman stated that third-quarter treatment volume landed roughly 20 basis points lower than anticipated, affected by increased hospitalizations and missed patient sessions, according to a report by Investing.com.
Despite these volume challenges, the company projects operating income for the fourth quarter to rise by approximately 30 million US dollars compared to the third quarter. Leadership noted that this sequential increase will stem entirely from its international activities and integrated kidney care segments. Meanwhile, core dialysis earnings are projected to remain relatively flat, weighed down by a substantial calendar-based decline in volume.
DaVita reported that its integrated kidney care division has surpassed expectations throughout 2026 and is positioned to deliver 20 million to 25 million US dollars in annual operating income going forward. International operations have also supported results, though third-quarter figures included non-recurring gains from Brazilian divestitures. Looking toward 2027, the company anticipates a 1.5 to 2 percent Medicare rate adjustment, alongside a 70 million US dollar headwind resulting from reduced commercial insurance exposure among newly initiated patients.
To help improve future patient trends, the healthcare company is introducing new dialyzer equipment intended to filter middle molecules while preserving proteins like albumin. Leadership expects this technology to reach the vast majority of eligible individuals in November, potentially boosting volume patterns over the coming years.
As of September 30, 2026, DaVita provided services to roughly 298,100 patients across 3,269 outpatient centers worldwide, including 2,671 facilities in the United States and 598 across 14 international markets. Shares closed at $183.50 on the NYSE on November 11, 2026.